Compare Amphastar Pharmaceuticals Inc (AMPH) vs Altria Group Inc (MO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs Altria Group Inc — how do they compare? Amphastar Pharmaceuticals Inc trades at $19.33 (market cap $826.08M), while Altria Group Inc trades at $72.27 (market cap $119.88B). The key difference: Altria Group Inc is far larger — about 145.1× Amphastar Pharmaceuticals Inc's market cap, and Altria Group Inc pays a 5.91% dividend while Amphastar Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMPH | MO | |
|---|---|---|
Market Cap | $826.08M | $119.88B |
Sector | Health | Consumer Staples |
52-Week High | $30.81 | $74.55 |
52-Week Low | $16.87 | $54.72 |
Enterprise Value | $1.22B | $140.95B |
Dividend Yield | — | 5.91% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.
The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.
Altria Group (MO) trades at $71.77, up 0.25% on the day, with a bullish technical signal and strong analyst support (16 buy ratings). The stock exhibits robust fundamentals, including a P/E of 14.99, net income margin of 39.52%, and consistent dividend payments, highlighted by a recent $1.06 dividend. Revenue remains stable around $20.1B, though net income dipped to $6.95B in 2025 from $11.3B in 2024. Positive cash flow of $1.33B in 2025 supports financial health, while technical indicators show support at $71 and resistance at $73.
Outlook: MO offers a compelling dividend yield and defensive appeal amid market volatility, but faces risks from declining smoking trends and regulatory pressures. Analyst consensus price target is $71.00, with potential upside to $79.00. Investors should weigh high debt levels and competitive threats against strong cash flow and brand loyalty for long-term income stability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About Altria Group Inc
Altria comprises Philip Morris USA, U.S. Smokeless Tobacco, John Middleton, Helix Innovations, and Philip Morris Capital, although the company plans to wind down Philip Morris Capital by the end of 2022. It holds a 10% interest in the world's largest brewer, Anheuser-Busch InBev. Through its tobacco subsidiaries, Altria holds the leading position in cigarettes and smokeless tobacco in the United States and the number-two spot in machine-made cigars. The company's Marlboro brand is the leading cigarette brand in the U.S. with a 43% share in 2020. Altria holds strategic investments in JUUL Labs (35% economic interest) and Cronos (42%).
Read more on MO →
